Prism MarketView

December 18, 2023 at 8:38 am

MindMed Advances Treatment for Generalized Anxiety Disorder

Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD)…. [Read More]

December 15, 2023 at 9:17 am

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic… [Read More]

December 14, 2023 at 11:19 am

CMS Establishes National Pricing for BioStem Technologies Product AmnioWrap2™

Leading regenerative medicine company, BioStem Technologies (OTC: BSEM), has announced that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2™,… [Read More]

December 14, 2023 at 9:04 am

C4 Therapeutics Achieves Positive Data in Multiple Myeloma Trial

C4 Therapeutics, Inc. (Nasdaq: CCCC) has reported positive clinical data from its ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of… [Read More]

December 13, 2023 at 11:34 am

PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan

Company continues to report progress with QRX003 clinical data in ongoing trials. Quoin Pharmaceuticals (Nasdaq:QNRX) has received U.S. Food and Drug Administration (FDA) clearance to… [Read More]

December 12, 2023 at 2:25 pm

Icosavax to be Acquired by AstraZeneca in Deal Valued at $1.1 Billion

Icosavax, Inc. (Nasdaq: ICVX) will be acquired by AstraZeneca in a deal with a total equity value of up to $1.1 billion. Today, Icosavax also… [Read More]

Women Hands Pictures | Prism Market View

December 11, 2023 at 3:00 pm

MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024

The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial of oral MYMD-1®… [Read More]

December 08, 2023 at 11:44 am

Exscientia Awarded $2.3M Grant for AI-Driven Pandemic Preparedness

Exscientia (Nasdaq: EXAI) has received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this… [Read More]

December 07, 2023 at 2:57 pm

Solid Biosciences Granted Fast Track Designation for Duchenne Gene Therapy Candidate

Solid Biosciences (Nasdaq: SLDB) has received FDA Fast Track Designation for SGT-003, the company’s next-generation Duchenne muscular dystrophy (DMD) gene therapy candidate. The company will… [Read More]

December 07, 2023 at 10:56 am

Aura Biosciences Advances Ocular Melanoma Treatment to Phase 3

Aura Biosciences (Nasdaq: AURA) has dosed the first patient in its global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the… [Read More]

December 06, 2023 at 3:02 pm

Oncocyte Starts FDA Submissions Process for Kidney Transplant Monitoring Test

Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), has initiated the FDA single-site process for its VitaGraft kidney transplant assays. This process is a well-established pathway… [Read More]

Pregnant Woman Group | Prism Market View

December 06, 2023 at 2:55 pm

Sera Prognostics Soars 205% as Trial is Halted Due to Efficacy

The Pregnancy Company®, Sera Prognostics Inc., (Nasdaq: SERA) has halted its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study… [Read More]

Tag: BIO TECH